What is the share price of Supriya Lifescience Ltd (SUPRIYA) today?
The share price of SUPRIYA as on 21st March 2025 is ₹726.25. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Supriya Lifescience Ltd (SUPRIYA) share?
The past returns of Supriya Lifescience Ltd (SUPRIYA) share are- Past 1 week: 7.98%
- Past 1 month: -4.40%
- Past 3 months: -0.49%
- Past 6 months: 15.70%
- Past 1 year: 116.15%
- Past 3 years: 54.18%
- Past 5 years: 85.81%
What are the peers or stocks similar to Supriya Lifescience Ltd (SUPRIYA)?
The peers or stocks similar to Supriya Lifescience Ltd (SUPRIYA) include:What is the dividend yield % of Supriya Lifescience Ltd (SUPRIYA) share?
The current dividend yield of Supriya Lifescience Ltd (SUPRIYA) is 0.11.What is the market cap of Supriya Lifescience Ltd (SUPRIYA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Supriya Lifescience Ltd (SUPRIYA) is ₹5845.06 Cr as of 21st March 2025.What is the 52 week high and low of Supriya Lifescience Ltd (SUPRIYA) share?
The 52-week high of Supriya Lifescience Ltd (SUPRIYA) is ₹835.20 and the 52-week low is ₹328.What is the PE and PB ratio of Supriya Lifescience Ltd (SUPRIYA) stock?
The P/E (price-to-earnings) ratio of Supriya Lifescience Ltd (SUPRIYA) is 49.07. The P/B (price-to-book) ratio is 7.17.Which sector does Supriya Lifescience Ltd (SUPRIYA) belong to?
Supriya Lifescience Ltd (SUPRIYA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Supriya Lifescience Ltd (SUPRIYA) shares?
You can directly buy Supriya Lifescience Ltd (SUPRIYA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Supriya Lifescience Ltd
SUPRIYA Share Price
726.2512.45% (+80.40)
SUPRIYA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SUPRIYA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SUPRIYA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.50 | 7.17 | 0.11% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.00 | 6.39 | 0.53% |
SUPRIYA Analyst Ratings & Forecast
Detailed Forecast 100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
SUPRIYA Company Profile
Supriya Lifescience is a manufacturer of pharmaceutical preparation.
Investor Presentation
View olderSUPRIYA Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
44.71
1Y Return
14.01%
Buy Reco %
88.24
CIPLA
PE Ratio
29.86
1Y Return
5.19%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
65.86
1Y Return
26.18%
Buy Reco %
68.00
DRREDDY
PE Ratio
17.93
1Y Return
2.08%
Buy Reco %
45.16
MANKIND
PE Ratio
52.09
1Y Return
13.24%
Buy Reco %
80.00
SUPRIYA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SUPRIYA Stock Summary · January 2025
Supriya Lifescience has demonstrated robust financial performance in Q3 FY '25, with a 33% year-on-year revenue increase to INR 186 crores, largely driven by strong export demand, particularly in the LATAM region, which now contributes 21% of total revenue. The company’s strategic focus on operational excellence and a backward integrated model has enhanced supply chain security and cost efficiency, allowing it to maintain healthy EBITDA and PAT margins despite pricing pressures in the API market. Future growth is bolstered by significant capital investments in new manufacturing capabilities and a commitment to expanding its product portfolio, particularly in regulated markets. As the company prepares for commercial production and new product launches, it aims to double revenue to INR 1,000 crores by FY '27, reflecting a proactive approach to market expansion and sustainability.
Key Points on SUPRIYA Stock Performance
SUPRIYA Stock Growth Drivers
7Strong Financial Performance
Supriya Lifescience Limited reported a significant 33% year-on-year increase in revenue from operations, reaching approximately
Export Growth and Market Expansion
Exports accounted for 85% of total revenue in Q3 FY '25, up from 74% in
SUPRIYA Stock Challenges
0
Hmm, looks like there are nochallenges
SUPRIYA Forecasts
Price
Revenue
Earnings
SUPRIYA Share Price Forecast
2024
Current
₹726.25
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹726.25
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SUPRIYA Company Revenue Forecast
2024
Current
₹581.01
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2024
Current
₹581.01
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
SUPRIYA Stock EPS (Earnings Per Share) Forecast
2024
Current
₹14.80
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹14.80
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
SUPRIYA
Income
Balance Sheet
Cash Flow
Annual Normal View
SUPRIYA Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 172.39 | 190.95 | 221.51 | 285.86 | 322.71 | 396.22 | 537.63 | 470.43 | 581.01 | 679.59 | ||||||||||
Raw Materials | 120.02 | 112.46 | 127.94 | 146.07 | 152.38 | 140.57 | 198.83 | 187.32 | 191.43 | 421.86 | ||||||||||
| Power & Fuel Cost | 6.64 | 6.93 | 7.03 | 0.00 | 8.97 | 9.24 | 14.07 | 20.95 | 21.37 | |||||||||||
| Employee Cost | 13.47 | 15.49 | 16.30 | 0.00 | 18.88 | 32.76 | 49.08 | 55.58 | 67.64 | |||||||||||
| Selling & Administrative Expenses | 9.53 | 8.11 | 15.85 | 0.00 | 30.10 | 31.88 | 33.83 | 37.32 | 39.43 | |||||||||||
| Operating & Other expenses | 0.67 | 23.39 | 23.84 | 67.03 | 2.92 | 3.62 | 20.25 | 30.87 | 74.48 | |||||||||||
EBITDA | 22.06 | 24.57 | 30.55 | 72.76 | 109.46 | 178.15 | 221.57 | 138.39 | 186.66 | 257.73 | ||||||||||
| Depreciation/Amortization | 3.95 | 4.75 | 5.33 | 5.44 | 6.41 | 6.76 | 10.12 | 11.82 | 15.81 | 18.27 | ||||||||||
| PBIT | 18.11 | 19.82 | 25.22 | 67.32 | 103.05 | 171.39 | 211.45 | 126.57 | 170.85 | 239.46 | ||||||||||
| Interest & Other Items | 10.04 | 11.76 | 10.75 | 10.22 | 6.85 | 4.08 | 4.20 | 3.08 | 5.15 | 1.88 | ||||||||||
| PBT | 8.07 | 8.06 | 14.47 | 57.10 | 96.20 | 167.31 | 207.25 | 123.49 | 165.70 | 237.58 | ||||||||||
| Taxes & Other Items | 2.36 | 2.40 | 5.74 | 17.68 | 22.84 | 43.71 | 55.44 | 33.63 | 46.58 | 63.09 | ||||||||||
| Net Income | 5.71 | 5.66 | 8.73 | 39.42 | 73.36 | 123.60 | 151.81 | 89.86 | 119.12 | 174.49 | ||||||||||
| EPS | 1.17 | 0.77 | 1.19 | 5.39 | 10.02 | 16.89 | 19.76 | 11.17 | 14.80 | 21.68 | ||||||||||
| DPS | 0.20 | 0.00 | 0.00 | 0.00 | 2.00 | 0.54 | 0.60 | 0.60 | 0.80 | 0.80 | ||||||||||
| Payout ratio | 0.17 | 0.00 | 0.00 | 0.00 | 0.20 | 0.03 | 0.03 | 0.05 | 0.05 | 0.04 |
SUPRIYA Company Updates
SUPRIYA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Supriya Lifescience Ltd | 49.07 | 7.17 | 0.11% |
| Sun Pharmaceutical Industries Ltd | 44.71 | 6.38 | 0.76% |
| Cipla Ltd | 29.86 | 4.59 | 0.85% |
| Torrent Pharmaceuticals Ltd | 65.86 | 15.91 | 0.87% |
SUPRIYA Stock Price Comparison
Compare SUPRIYA with any stock or ETFCompare SUPRIYA with any stock or ETF
SUPRIYA
SUPRIYA Shareholdings
SUPRIYA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SUPRIYA Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 15.41%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SUPRIYA Shareholding Pattern
SUPRIYA Shareholding History
Foreign Institutions
Mutual Funds Invested in SUPRIYA
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Supriya Lifescience Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2713% | Percentage of the fund’s portfolio invested in the stock 1.80% | Change in the portfolio weight of the stock over the last 3 months -0.22% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/96 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1147% | Percentage of the fund’s portfolio invested in the stock 1.59% | Change in the portfolio weight of the stock over the last 3 months -0.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/86 (+25) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0636% | Percentage of the fund’s portfolio invested in the stock 2.38% | Change in the portfolio weight of the stock over the last 3 months 2.38% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/51 (+13) |
Compare 3-month MF holding change on Screener
smallcases containing SUPRIYA stock
Looks like this stock is not in any smallcase yet.
SUPRIYA Events
SUPRIYA Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.10 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SUPRIYA Upcoming Dividends
No upcoming dividends are available
SUPRIYA Past Dividends
Cash Dividend
Ex DateEx DateSep 20, 2024
Final
Final | Div/Share: ₹0.80
Dividend/Share
₹0.80
Ex DateEx Date
Sep 20, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 1, 2022
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 1, 2022
SUPRIYA Stock News & Opinions
Articles & Videos
Corporate
Board of Supriya Lifescience appoints company secretary and compliance officer
The Board of Supriya Lifescience at its meeting held on 10 March 2025 has approved the appointment of Prachi Sathe bearing Membership No. A-70252 as Company Secretary and Compliance Officer of the Company with effect from 10 March 2025. Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Supriya Lifesciences to hold board meeting
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 10 March 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 57.03% in the December 2024 quarter
Net profit of Supriya Lifescience rose 57.03% to Rs 46.78 crore in the quarter ended December 2024 as against Rs 29.79 crore during the previous quarter ended December 2023. Sales rose 32.54% to Rs 185.65 crore in the quarter ended December 2024 as against Rs 140.07 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales185.65140.07 33 OPM %35.5229.62 - PBDT67.5444.07 53 PBT62.5840.11 56 NP46.7829.79 57 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Supriya Lifesciences declare Quarterly Result
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Supriya Lifescience inaugurates new API production block at Lote Parshuram site
Supriya Lifescience inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately Rs 125 crore, adds a substantial capacity of 335 kiloliters to the company's operations. This expansion boosts its Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Supriya Life gains after bagging approval from ANVISA for Esketamine Hydrochloride
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. The company said that it is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Satish Wagh, executive chairman and whole time director, Supriya Lifescience, stated, Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil. Supriya Lifesciences is primarily engaged in manufacturing of Bulk drugs and pharmaceutical chemicals. The company's standalone net profit jumped 93.3% to Rs 46.15 crore in Q2 FY25 as compared with Rs 23.88 crore in Q2 FY24. Net sales increased 18.6% YoY to Rs 166.10 crore in Q2 FY25.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 93.26% in the September 2024 quarter
Net profit of Supriya Lifescience rose 93.26% to Rs 46.15 crore in the quarter ended September 2024 as against Rs 23.88 crore during the previous quarter ended September 2023. Sales rose 18.56% to Rs 166.10 crore in the quarter ended September 2024 as against Rs 140.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales166.10140.10 19 OPM %38.9622.66 - PBDT66.8133.76 98 PBT62.0729.78 108 NP46.1523.88 93 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Supriya Lifesciences to announce Quarterly Result
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Supriya Lifesciences to hold AGM
Supriya Lifesciences announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 56.58% in the June 2024 quarter
Net profit of Supriya Lifescience rose 56.58% to Rs 44.64 crore in the quarter ended June 2024 as against Rs 28.51 crore during the previous quarter ended June 2023. Sales rose 21.67% to Rs 160.63 crore in the quarter ended June 2024 as against Rs 132.02 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales160.63132.02 22 OPM %38.9433.50 - PBDT64.4346.59 38 PBT59.7742.63 40 NP44.6428.51 57 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.24%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.13% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of 24.75%, vs industry avg of 15.28%